全文获取类型
收费全文 | 3480篇 |
免费 | 203篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 173篇 |
妇产科学 | 30篇 |
基础医学 | 368篇 |
口腔科学 | 79篇 |
临床医学 | 430篇 |
内科学 | 741篇 |
皮肤病学 | 54篇 |
神经病学 | 185篇 |
特种医学 | 573篇 |
外国民族医学 | 1篇 |
外科学 | 412篇 |
综合类 | 55篇 |
一般理论 | 2篇 |
预防医学 | 227篇 |
眼科学 | 40篇 |
药学 | 141篇 |
中国医学 | 5篇 |
肿瘤学 | 183篇 |
出版年
2022年 | 14篇 |
2021年 | 52篇 |
2020年 | 28篇 |
2019年 | 36篇 |
2018年 | 55篇 |
2017年 | 34篇 |
2016年 | 42篇 |
2015年 | 59篇 |
2014年 | 73篇 |
2013年 | 143篇 |
2012年 | 95篇 |
2011年 | 109篇 |
2010年 | 117篇 |
2009年 | 96篇 |
2008年 | 105篇 |
2007年 | 106篇 |
2006年 | 133篇 |
2005年 | 98篇 |
2004年 | 103篇 |
2003年 | 109篇 |
2002年 | 97篇 |
2001年 | 78篇 |
2000年 | 88篇 |
1999年 | 79篇 |
1998年 | 155篇 |
1997年 | 131篇 |
1996年 | 139篇 |
1995年 | 102篇 |
1994年 | 85篇 |
1993年 | 93篇 |
1992年 | 49篇 |
1991年 | 53篇 |
1990年 | 40篇 |
1989年 | 83篇 |
1988年 | 58篇 |
1987年 | 73篇 |
1986年 | 56篇 |
1985年 | 66篇 |
1984年 | 37篇 |
1983年 | 45篇 |
1982年 | 44篇 |
1981年 | 24篇 |
1980年 | 44篇 |
1979年 | 24篇 |
1978年 | 20篇 |
1977年 | 25篇 |
1976年 | 30篇 |
1975年 | 34篇 |
1973年 | 20篇 |
1919年 | 16篇 |
排序方式: 共有3707条查询结果,搜索用时 0 毫秒
91.
92.
93.
94.
95.
96.
97.
J Tang DJ Humes E Gemmil NT Welch SL Parsons JA Catton 《Annals of the Royal College of Surgeons of England》2013,95(5):323-328
Introduction
The high mortality and morbidity associated with resection for oesophagogastric malignancy has resulted in a conservative approach to the postoperative management of this patient group. In August 2009 we introduced an enhanced recovery after surgery (ERAS) pathway tailored to patients undergoing resection for oesophagogastric malignancy. We aimed to assess the impact of this change in practice on standard clinical outcomes.Methods
Two cohorts were studied of patients undergoing resection for oesophagogastric malignancy before (August 2008 – July 2009) and after (August 2009 – July 2010) the implementation of the ERAS pathway. Data were collected on demographics, interventions, length of stay, morbidity and in-hospital mortality.Results
There were 53 and 55 oesophagogastric resections undertaken respectively for malignant disease in each of the study periods. The median length of stay for both gastric and oesophageal resection decreased from 15 to 11 days (Mann– Whitney U, p<0.001) following implementation of the ERAS pathway. There was no significant increase in morbidity (gastric resection 23.1% vs 5.3% and oesophageal resection 25.9% vs 16.7%) or mortality (gastric resection no deaths and oesophageal resection 1.8% vs 3.6%) associated with the changes. There was a significant decrease in the number of oral contrast studies used following oesophageal resection, with a reduction from 21 (77.8%) in 2008–2009 to 6 (16.7%) in 2009–2010 (chi-squared test, p<0.0001).Conclusions
The introduction of an enhanced recovery programme following oesophagogastric surgery resulted in a significant decrease in length of median patient stay in hospital without a significant increase in associated morbidity and mortality. 相似文献98.
A Besarab SN Zeig ER Martin PE Pergola FC Whittier RI Zabaneh B Schiller M Mayo CA Francisco KR Polu AM Duliege 《BMC nephrology》2012,13(1):95
ABSTRACT: BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this phase 2 dose-finding study was to determine the once-monthly peginesatide dosing strategy that would maintain hemoglobin within [PLUS-MINUS SIGN]1.0 g/dL of baseline values after conversion from epoetin alfa; the safety of peginesatide was evaluated concurrently. METHODS: Chronic hemodialysis patients on stable regimens of epoetin alfa were sequentially assigned to cohorts that differed on (1) how the peginesatide starting dose was determined (using a single epoetin alfa--to-peginesatide dose conversion ratio or a tiered, weight-based or absolute-dose conversion table) and on (2) whether or not a 1-week erythropoiesis-stimulating agent-free interval was used. Peginesatide doses were titrated to maintain hemoglobin levels within [PLUS-MINUS SIGN]1.0 g/dL from baseline. RESULTS: A total of 164 patients were enrolled and received intravenous peginesatide every 4 weeks for up to 6 doses; the duration of the study including follow-up was [LESS-THAN OR EQUAL TO]29 weeks. Overall, the proportion of patients with hemoglobin levels within [PLUS-MINUS SIGN]1.0 g/dL of baseline increased over the course of the study from 39% (Weeks 2--13) to 54% (Weeks 18--25). Cohorts that used tiered dose conversion tables trended towards having more stable peginesatide doses than did those cohorts that used a single dose conversion ratio. Moreover, cohorts that used an erythropoiesis-stimulating agent-free interval did not have the substantial initial increase in hemoglobin levels that was seen in those cohorts that did not use such an interval. In this study, the safety profile of peginesatide was consistent with those of marketed erythropoiesis-stimulating agents. CONCLUSIONS: The results of this study were used to guide the dosing regimens used subsequently in phase 3 studies. Once-monthly peginesatide is feasible in hemodialysis patients.Trial registrationClinicalTrials.gov registration: NCT00228449. 相似文献
99.
Summary
This study provides evidence that a number of frailty-related characteristics (older age, de novo admission to long-term care (LTC), comorbidities [Charlson Index, osteoporosis, osteoporosis risk factors, sarcopenia risk factors, and dementia]) have increased in the hip fracture population from 2001–2008. This will have significant impact on community resources, as the number of people discharged to the community is also increasing.Introduction
The aim of this study is to estimate secular changes in the prevalence of selected frailty-related characteristics among the hip fracture population in the Canadian province of Quebec (2001–2008) and the potential impact of these changes on healthcare services.Methods
The Quebec hospitalization database was used to identify nontraumatic hip fractures for the purposes of calculating age- and sex-specific rates. Also estimated were time trends for selected frailty-related characteristics and discharge destinations.Results
A significant decline in fracture rates was evident for all age groups except for those <65; sex differences were also observed. Almost all frailty-related characteristics increased over time, ranging from 2 to 14 % per year, which translates to an estimated increase from 16 to 112 %, over the study period. For those whose prior living arrangement was LTC, rates of hip fractures declined significantly (women OR?=?0.93, 0.91–0.95; men OR?=?0.97, 0.94–0.99). In-hospital mortality and discharge to inpatient rehabilitation decreased, while discharges back to community and to LTC increased.Conclusions
Although hip fracture rates decreased for older hip fracture patients, the absolute number and prevalence of specific frailty-related characteristics increased. Policy makers should review care models to ensure that adequate resources are provided to the community to offset the expected increase in demand arising from ongoing changes in patients’ characteristics. 相似文献100.